We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

123 hedge funds and large institutions have $399M invested in Keryx Biopharmaceuticals Inc in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 38 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

13% more capital invested

Capital invested by funds: $354M → $399M (+$44.8M)

6% more funds holding

Funds holding: 116123 (+7)

5% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 38

30% less call options, than puts

Call options by funds: $3.06M | Put options by funds: $4.37M

Holders
123
Holders Change
+7
Holders Change %
+6.03%
% of All Funds
3.07%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
19
Increased
36
Reduced
38
Closed
12
Calls
$3.06M
Puts
$4.37M
Net Calls
-$1.31M
Net Calls Change
-$776K
Name Holding Trade Value Shares
Change
Change in
Stake
QIM
26
Quantitative Investment Management
Virginia
$1.34M +$1.25M +229,600 New
IAM
27
Iridian Asset Management
Connecticut
$1.34M +$1.25M +228,570 New
TCIM
28
TIAA CREF Investment Management
New York
$1.33M -$59.4K -10,862 -5%
OWIM
29
Old West Investment Management
California
$1.23M +$401K +73,405 +54%
California Public Employees Retirement System
30
California Public Employees Retirement System
California
$1.2M
KCM
31
Knoll Capital Management
Florida
$1.17M
JP Morgan Chase
32
JP Morgan Chase
New York
$1.17M +$800K +146,432 +275%
D.E. Shaw & Co
33
D.E. Shaw & Co
New York
$1.06M +$834K +152,588 +551%
HS
34
HighVista Strategies
Massachusetts
$1M -$293K -53,700 -24%
VEA
35
Virtus ETF Advisers
New York
$974K +$330K +60,346 +57%
First Trust Advisors
36
First Trust Advisors
Illinois
$962K +$897K +164,181 New
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$954K -$23.5K -4,300 -3%
AllianceBernstein
38
AllianceBernstein
Tennessee
$875K
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$824K
TA
40
Teachers Advisors
New York
$814K +$24.1K +4,402 +3%
Swiss National Bank
41
Swiss National Bank
Switzerland
$765K -$81.4K -14,900 -10%
Bank of America
42
Bank of America
North Carolina
$765K +$38.7K +7,086 +6%
PPA
43
Parametric Portfolio Associates
Washington
$706K +$529K +96,842 +409%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$543K -$7.91K -1,448 -2%
SEI Investments
45
SEI Investments
Pennsylvania
$488K +$452K +82,700 +16,843%
CCP
46
Clough Capital Partners
Massachusetts
$461K +$246K +45,000 +134%
CS
47
Credit Suisse
Switzerland
$457K +$154K +28,195 +57%
GAM
48
Gotham Asset Management
New York
$450K +$419K +76,726 New
SRC
49
Shufro Rose & Co
New York
$426K +$2.73K +500 +0.7%
FWM
50
Frontier Wealth Management
Missouri
$421K -$25.1K -4,600 -6%

KERX Hedge Fund Activity: Q4 2016 in Review

123 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q4 2016, worth a combined $399M — up 13% from $354M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new KERX positions and 12 closed out — a net gain of 7 holders — while 36 added to existing stakes and 38 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $7.06M. The largest seller was Fidelity Investments, cutting an estimated $3.82M.

  • 123 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q4 2016, up from 116 in Q3 2016.
  • Funds reported $399M of Keryx Biopharmaceuticals Inc stock for Q4 2016, up 13% quarter-over-quarter.
  • 19 funds opened new Keryx Biopharmaceuticals Inc positions in Q4 2016 and 12 closed out, a net change of +7 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q4 2016 was Deerfield Management, an estimated $7.06M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q4 2016 was Fidelity Investments, an estimated $3.82M sold.

Based on aggregated 13F filings for Q4 2016.